Lyra Therapeutics, Inc. (LYRA) intrinsic value & 10-year financials
Lyra Therapeutics, Inc. (LYRA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 8.7% a year to $398.0K, with an average return on invested capital of -8235.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.19
- Market cap
- $295.2K
- Revenue (FY2025)
- $398.0K
- Revenue growth (8-yr CAGR)
- 8.7%
- ROIC (10-yr avg)
- -8235.5%
- Free cash flow (FY2025)
- -$29.0M
LYRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $398.0K | -$28.9M | -$18.62 | -$29.0M | -7794.5% | -57985.0% |
| FY2024 | $1.5M | -$93.4M | -$1.43 | -$72.3M | -6280.8% | -214.6% |
| FY2023 | $1.6M | -$62.7M | -$1.26 | -$64.4M | -4308.1% | -97.7% |
| FY2022 | $1.4M | -$55.3M | -$1.83 | -$43.5M | -4131.0% | -297.8% |
| FY2021 | $285.0K | -$43.5M | -$3.35 | -$29.2M | -15303.5% | 899.4% |
| FY2020 | — | -$22.1M | — | -$22.9M | — | 34.3% |
| FY2019 | — | -$16.3M | — | -$14.0M | — | 12.6% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lyra Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lyra Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -89.5% ROIC.
Lyra Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Lyra Therapeutics, Inc. is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-393.58 per share.